BIOTON S.A. (DE:7U5)

FRANKFURT:7U5

7U5

BIOTON S.A.

RESEARCH TOOLSreports

BIOTON S.A. (7U5) Price & Analysis

0 Followers

7U5 Stock Chart & Stats

€0.97

€0.01(1.66%)

At close: Jan 08 4:00 PM EST

€0.97

€0.01(1.66%)

Day’s Range― - ―

52-Week Range€0.87 - €1.15

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€78.60M

Enterprise Value€398.30M

Total Cash (Recent Filing)€2.61M

Total Debt (Recent Filing)€58.75M

Price to Earnings (P/E)81.5

Beta0.27

Next Earnings

Sep 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.05

Shares Outstanding85,864,200

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.80

Price to Book (P/B)0.56

Price to Sales (P/S)1.17

P/FCF Ratio145.62

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.03

Revenue Forecast (FY)€63.15M

Bulls Say, Bears Say

Bulls Say

Low LeverageA conservative leverage approach provides BIOTON with financial flexibility and reduces risk, supporting long-term sustainability.

Cash Flow ImprovementImproved cash flow generation enhances BIOTON's ability to reinvest in growth opportunities and maintain financial stability.

Revenue GrowthStrong revenue growth indicates increasing demand for BIOTON's products, enhancing its market position and potential for future expansion.

Bears Say

Low Operating Cash FlowLow operating cash flow relative to net income suggests that BIOTON may struggle to cover its operational expenses, affecting financial health.

Negative Net IncomeNegative net income reflects operational inefficiencies, which can hinder BIOTON's ability to invest in growth and return value to shareholders.

Declining Profit MarginsDecreasing profit margins indicate challenges in cost management and pricing power, potentially impacting long-term profitability.

7U5 FAQ

What was BIOTON S.A.’s price range in the past 12 months?

BIOTON S.A. lowest stock price was €0.87 and its highest was €1.15 in the past 12 months.

What is BIOTON S.A.’s market cap?

BIOTON S.A.’s market cap is €78.60M.

When is BIOTON S.A.’s upcoming earnings report date?

BIOTON S.A.’s upcoming earnings report date is Sep 15, 2026 which is in 82 days.

How were BIOTON S.A.’s earnings last quarter?

BIOTON S.A. released its earnings results on May 29, 2026. The company reported -€0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.014.

Is BIOTON S.A. overvalued?

According to Wall Street analysts BIOTON S.A.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BIOTON S.A. pay dividends?

BIOTON S.A. does not currently pay dividends.

What is BIOTON S.A.’s EPS estimate?

BIOTON S.A.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BIOTON S.A. have?

BIOTON S.A. has 85,864,200 shares outstanding.

What happened to BIOTON S.A.’s price movement after its last earnings report?

BIOTON S.A. reported an EPS of -€0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.395%.

Which hedge fund is a major shareholder of BIOTON S.A.?

Currently, no hedge funds are holding shares in DE:7U5

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BIOTON S.A.

Bioton S.A. operates as a biotechnology company, engaged in the creation, production, distribution, and commercialization of a diverse array of pharmaceuticals, medicinal preparations, and active pharmaceutical ingredients. Its primary focus is on diabetes management, offering products such as recombinant human and conventional insulin, alongside oral anti-diabetic medications. The company's portfolio extends to include dietary supplements, blood glucose monitoring strips, and over-the-counter solutions for diabetics. Key insulin products include Gensulin N, Gensulin R, and Gensulin M30, available in vials and cartridges. Complementing these are advanced delivery and monitoring systems like the GensuPen 2 automatic injection device and the GensuCare glucometer for diabetes monitoring, alongside essential needles. Bioton S.A. distributes its offerings across numerous international markets, including Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. Beyond its core product activities, the company also undertakes advertising, advisory services, and general corporate management. Founded in 1989, its headquarters are situated in Ozarów Mazowiecki, Poland.